Company profile
Home | Apobec Discovery
Targeting the key APOBEC enzymes that are a principle cause of cancer development, evolution, spread and cancer treatment resistance.
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
CS01 | Transaction MzQ0MzEyOTk2OWFkaXF6a2N4
Published 13 Nov 2024 05:57
AP01 | Transaction MzQ0MzEwODM2NmFkaXF6a2N4
Published 13 Nov 2024 04:54
SH01 | Transaction MzQ0MzA5ODY3NWFkaXF6a2N4
Published 13 Nov 2024 04:29
RESOLUTIONS | Transaction QURFRkI4WERhZGlxemtjeA | Paper/PDF filed
Published 05 Nov 2024 07:08
Company registered at Companies House
1 Oct 2021 to 31 Mar 2022
APOBEC proteins have been recently recognised as the most significant cause of cancer, even more so than smoking or UV radiation. The genetic mutations driven be APOBEC are not only the cause and growth of many common cancers, but also their spread and the development of drug treatment resistance in the cancer. There are currently no medical treatments ap...
